A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
about
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesA 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies.A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPETProstate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.Inducible expression of cancer-testis antigens in human prostate cancer.Prostate Cancer Imaging with Novel PET Tracers.A Feasibility Study Showing [(68)Ga]Citrate PET Detects Prostate Cancer.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseAntibody therapeutics for treating prostate cancer: where are we now and what comes next?Advancing Immune and Cell-Based Therapies Through Imaging.Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry.PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model.Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen.Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases.Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent.Interventional Molecular Imaging.Rapid PD-L1 detection in tumors with PET using a highly specific peptide.Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.PSMA Theranostics: Current Status and Future Directions.Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges
P2860
Q26744088-0E255B17-FA71-4BEC-A0D7-33DEEAB89A46Q28067404-A192C3E5-62C8-4091-B02B-04B972F119C4Q30491961-2C187EB9-F493-43E7-82B6-1D73D2A1150AQ36363280-6AB88BB3-DC5A-4F68-882F-98C2AEF85874Q36874190-08539499-1711-45BB-AA4B-797E55A011CFQ37022167-13EDA177-A703-4299-ADAC-BE4B3A5BA39CQ37129847-379D860B-3C62-430C-95A0-81083F0CBC2BQ37390674-B4DEB398-5B2C-4194-9244-46565778CB84Q37686238-38E26541-E62E-422B-8B50-99EC8C548C35Q38732369-39E327C1-935A-4558-8BCD-BD0BE6600B17Q38800196-E27CD903-16CC-4F2E-97FB-EA5DAB2B3311Q38831232-8925E836-94CD-471D-BD04-1942CC08DDBAQ39000185-CEFB3069-2D23-481A-8C25-39AC18C729CBQ39167485-D875922C-9208-4ADA-84B0-65622DAB8F2FQ39780216-F20CE9DB-F30F-40B9-90D4-D73B8F26F466Q40208474-754FA045-24E5-4CFD-B5DF-8FE49F81D008Q41653596-70473BE3-D255-466A-90F8-EBDB84FF609DQ41690954-E7844847-D9F0-4A1A-8551-D39B29E04ACBQ42114642-129AD4A2-00DF-410F-93ED-DB367548A617Q42756624-53FFF2CF-E1D2-4428-85AE-2027CB73CF91Q47105948-567BEF30-EF50-465B-8EDA-7077C273BA74Q47257677-807E7CE0-F4BA-4544-97BD-51D10F9CBC6DQ47270020-3791BB4B-0CBC-4DE7-B238-2E8B9127CE08Q47399023-91CC1C9F-4F86-4BB4-B770-F9041191C067Q48136353-C4D4E302-D20C-4986-ADDC-EE1AFFAF6B25Q49827187-93C9B3E4-A61C-4B56-9B76-6C36BA8F3F89Q51006855-CB447BE3-EDB5-47E0-82E8-DBE44F66E841Q51234651-9B491601-DC5C-4122-BDD3-307897ECAB47Q52816283-D8332E67-058A-4816-A4C0-68E6EE18353CQ53106375-50E266AB-AEC9-4D61-A75B-E5406B0CC623Q53163035-0694FD46-AA14-4C45-B8F2-670B9E35DB3BQ55023828-A4000738-7034-43E1-96D0-C51AC015B7E9Q57107208-6F94EF82-D42D-4188-9986-572D32EE3458
P2860
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A Phase I/II Study for Analyti ...... or Metastatic Prostate Cancer.
@en
type
label
A Phase I/II Study for Analyti ...... or Metastatic Prostate Cancer.
@en
prefLabel
A Phase I/II Study for Analyti ...... or Metastatic Prostate Cancer.
@en
P2093
P2860
P50
P1476
A Phase I/II Study for Analyti ...... or Metastatic Prostate Cancer.
@en
P2093
Alex Mak Fung
Danny F Martinez
David M Nanus
Glenn Heller
Howard I Scher
Jarett L Feldman
Mithat Gönen
Neeta Pandit-Taskar
Neil H Bander
Robert A Lefkowitz
P2860
P304
P356
10.1158/1078-0432.CCR-15-0552
P407
P50
P577
2015-07-14T00:00:00Z